Successful use of tigecycline for treatment of culture-negative pyogenic vertebral osteomyelitis

References

• Cheung WY, Luk KD. Pyogenic spondylitis. Int Orthop 2012;36:397–404.
   PubMed Web of Science ®Google Scholar
• Zimmerli W. Vertebral osteomyelitis. N Engl J Med 2010;362:1022–9.
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo J, Euba G, Narváez JA, Murillo O, Verdaguer R, Sobrino B, et al. Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum 2011;41: 247–55.
   PubMedGoogle Scholar
• Bhagat S, Mathieson C, Jandhyala R, Johnston R. Spondylodiscitis (disc space infection) associated with negative microbiological tests: comparison of outcome of suspected disc space infections to documented non-tuberculous pyogenic discitis. Br J Neurosurg 2007;21:473–7.
   PubMed Web of Science ®Google Scholar
• Fantoni M, Trecarichi EM, Rossi B, Mazzotta V, Di Giacomo G, Nasto LA, et al. Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 2012;16(Suppl 2):2–7.
   PubMedGoogle Scholar
• Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother 2010;65(Suppl 3):11–24.
   Google Scholar
• Kim J, Kim YS, Peck KR, Kim ES, Cho SY, Ha YE, et al. Outcome of culture-negative pyogenic vertebral osteomyelitis: comparison with microbiologically confirmed pyogenic vertebral osteomyelitis. Semin Arthritis Rheum 2014;44: 246–52.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Chung SK, Kim KJ, Kim HJ, Jin YJ, Kim HB. Pyogenic vertebral osteomyelitis: identification of microorganism and laboratory markers used to predict clinical outcome. Eur Spine J 2010;19:575–82.
   PubMedGoogle Scholar
• Kehrer M, Pedersen C, Jensen TG, Lassen AT. Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect 2014;68:313–20.
   PubMed Web of Science ®Google Scholar
• Fritz JM, Irrgang JJ. A comparison of a modified Oswestry Low Back Pain Disability Questionnaire and the Quebec Back Pain Disability Scale. Phys Ther 2001;81:776–88.
   PubMed Web of Science ®Google Scholar
• Lebre A, Velez J, Rabadão E, Oliveira J, Cunha JS, Silvestre AM. Infectious spondylodiscitis: a retrospective study of 140 patients. Infect Dis Clin Pract 2014;22:223–8.
   Google Scholar
• Aagaard T, Roed C, Dragsted C, Skinhøj P. Microbiological and therapeutic challenges in infectious spondylodiscitis: a cohort study of 100 cases, 2006–2011. Scand J Infect Dis 2013;45:417–24.
   PubMed Web of Science ®Google Scholar
• Moffa M, Brook I. Tetracyclines, glycylcyclines and chloramphenicol. In: Bennett JE, Dolin R, Blaser MJ, editors. Principles and practice of infectious diseases, 8th edn. Churchill Livingstone; 2015 pp 322–38.
   Google Scholar
• Sipahi OR, Kahraman H, Mermer S, Pullukcu H, Tasbakan M, Arda B, et al. Tigecycline in the management of post-neurosurgical spondylodiscitis: a review of eight cases. Int J Infect Dis 2014;23:16–19.
   PubMed Web of Science ®Google Scholar
• Griffin AT, Harting JA, Christensen DM. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diagn Microbiol Infect Dis 2013;77:273–7.
   PubMedGoogle Scholar
• Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005;55:995–1002.
   PubMed Web of Science ®Google Scholar
• Kandemir O, Oztuna V, Colak M, Akdag A, Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53–7.
   PubMed Web of Science ®Google Scholar
• Bhattacharya I, Gotfried MH, Ji AJ, Saunders JP, Gourley I, Diehl A, et al. Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. J Clin Pharmacol 2014;54:70–4.
   PubMedGoogle Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221–9.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008; 14:512–14.
   PubMed Web of Science ®Google Scholar
• Chen PL, Yan JJ, Wu CJ, Lee HC, Chang CM, Lee NY, et al. Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2010;68:312–14.
   PubMedGoogle Scholar
• Cottle L, Riordan T. Infectious spondylodiscitis. J Infect 2008;56:401–12.
   PubMed Web of Science ®Google Scholar
• Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P. Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine 2007;74: 133–9.
   PubMed Web of Science ®Google Scholar
• Luzzati R, Giacomazzi D, Danci MC, Tacconi L, Concia E, Vento S. Diagnosis, management and outcomes of clinically-suspected spinal infections. J Infect 2009;58:259–65.
   PubMed Web of Science ®Google Scholar
• Zarghooni K, Röllinghoff M, Sobottke R, Eysel P. Treatment of spondylodiscitis. Int Orthop 2012;36:405–11.
   PubMed Web of Science ®Google Scholar
• Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum 2007; 36:269–77.
   PubMed Web of Science ®Google Scholar